A PYMNTS Company

US: Allergan seeks new buyout to foil Valeant’s takeover plans

By  |  June 19, 2014

US pharmaceutical conglomerate Allergan is reportedly looking to foil Canadian rival Valeant’s plans to acquire the US company, now pursuing a merger of its own.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Allergan is reportedly looking to acquire Ireland’s Shire, news that caused Valeant shares to fall Wednesday.

    Experts say the Botox maker could acquire Shire to broaden its portfolio into rare disease treatment, a more attractive plan than Valeant’s hostile takeover bid. Reports say Allergan’s rumored plan is expected to reveal itself with an “imminent” formal bid.

    Full content: Leader Post

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.